INCR
Price
$1.63
Change
-$0.03 (-1.81%)
Updated
Aug 15 closing price
Capitalization
88.86M
One day until earnings call
TLRY
Price
$1.03
Change
-$0.15 (-12.71%)
Updated
Aug 15 closing price
Capitalization
1.13B
45 days until earnings call
Interact to see
Advertisement

INCR vs TLRY

Header iconINCR vs TLRY Comparison
Open Charts INCR vs TLRYBanner chart's image
Intercure
Price$1.63
Change-$0.03 (-1.81%)
Volume$25.16K
Capitalization88.86M
Tilray Brands
Price$1.03
Change-$0.15 (-12.71%)
Volume$90.05M
Capitalization1.13B
INCR vs TLRY Comparison Chart in %
Loading...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCR vs. TLRY commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (INCR: $1.63 vs. TLRY: $1.03)
Brand notoriety: INCR: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: INCR: 71% vs. TLRY: 166%
Market capitalization -- INCR: $88.86M vs. TLRY: $1.13B
INCR [@Pharmaceuticals: Generic] is valued at $88.86M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.13B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCR’s FA Score shows that 1 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • INCR’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, INCR is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCR’s TA Score shows that 5 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • INCR’s TA Score: 5 bullish, 5 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both INCR and TLRY are a good buy in the short-term.

Price Growth

INCR (@Pharmaceuticals: Generic) experienced а +8.67% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +58.78% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

INCR is expected to report earnings on Aug 18, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.13B) has a higher market cap than INCR($88.9M). INCR YTD gains are higher at: 2.516 vs. TLRY (-22.556).
INCRTLRYINCR / TLRY
Capitalization88.9M1.13B8%
EBITDAN/A-2.13B-
Gain YTD2.516-22.556-11%
P/E Ratio24.99N/A-
RevenueN/A821M-
Total CashN/A256M-
Total DebtN/A329M-
FUNDAMENTALS RATINGS
INCR vs TLRY: Fundamental Ratings
INCR
TLRY
OUTLOOK RATING
1..100
1419
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8698
PRICE GROWTH RATING
1..100
5035
P/E GROWTH RATING
1..100
594
SEASONALITY SCORE
1..100
3650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (53) in the Biotechnology industry is in the same range as INCR (61) in the Servicestothe Health Industry industry. This means that TLRY’s stock grew similarly to INCR’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that TLRY’s stock grew similarly to INCR’s over the last 12 months.

INCR's SMR Rating (86) in the Servicestothe Health Industry industry is in the same range as TLRY (98) in the Biotechnology industry. This means that INCR’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as INCR (50) in the Servicestothe Health Industry industry. This means that TLRY’s stock grew similarly to INCR’s over the last 12 months.

INCR's P/E Growth Rating (5) in the Servicestothe Health Industry industry is significantly better than the same rating for TLRY (94) in the Biotechnology industry. This means that INCR’s stock grew significantly faster than TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCRTLRY
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
73%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 18 days ago
80%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GLPEY9.420.08
+0.88%
Galp Energia, SA
NDGPY12.30N/A
N/A
Nine Dragons Paper Holdings Ltd.
SQZB0.03N/A
N/A
SQZ Biotechnologies Company
HYPRF0.95N/A
N/A
Hydrogenpro AS
FECCF4.28-0.06
-1.43%
Frontera Energy Corp

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and PHCUF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and PHCUF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
-1.81%
PHCUF - INCR
26%
Poorly correlated
N/A
AKAN - INCR
23%
Poorly correlated
N/A
TLRY - INCR
22%
Poorly correlated
-12.71%
QNTM - INCR
22%
Poorly correlated
+0.45%
CGC - INCR
21%
Poorly correlated
-12.75%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been loosely correlated with CGC. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if TLRY jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
-12.71%
CGC - TLRY
62%
Loosely correlated
-12.75%
CRON - TLRY
61%
Loosely correlated
-5.95%
OGI - TLRY
57%
Loosely correlated
-8.33%
ACB - TLRY
56%
Loosely correlated
-5.75%
VTRS - TLRY
34%
Loosely correlated
-0.75%
More